Back to mobile site

Abivax (ABVX) Reiterated at Market Outperform by Citizens on Positive ABTECT Data

July 1, 2026 4:39 AM EDT Send to a Friend
Citizens analyst Jason Butler reiterated a Market Outperform rating and $187.00 price target on Abivax (NASDAQ: ABVX).The analyst commented, "Insights ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login